Company Overview - Harbin Sanlian Pharmaceutical Co., Ltd. is located in Harbin, Heilongjiang Province, established on June 21, 1996, and listed on September 22, 2017. The company specializes in the research, production, and sales of chemical drug formulations [1][2]. Financial Performance - As of November 10, 2023, Harbin Sanlian reported a revenue of 581 million yuan for the period from January to September 2025, a year-on-year decrease of 30.75%. The net profit attributable to the parent company was -209 million yuan, a significant decline of 614.61% [2]. - The company has cumulatively distributed 677 million yuan in dividends since its A-share listing, with 158 million yuan distributed over the past three years [3]. Stock Performance - On November 18, 2023, Harbin Sanlian's stock price increased by 2.34%, reaching 14.89 yuan per share, with a trading volume of 52.42 million yuan and a turnover rate of 2.05%. The total market capitalization stood at 4.711 billion yuan [1]. - Year-to-date, the stock price has risen by 54.30%, with a 2.69% increase over the last five trading days and a 12.12% increase over the last 20 days. However, it has seen a decline of 1.72% over the past 60 days [1]. Shareholder Information - As of November 10, 2023, the number of shareholders for Harbin Sanlian was 39,600, a decrease of 2.98% from the previous period. The average number of circulating shares per person increased by 3.07% to 4,419 shares [2]. Business Segmentation - The main revenue sources for Harbin Sanlian include: large-volume injections (32.00%), lyophilized powder injections (18.39%), solid preparations (17.39%), small-volume injections (14.34%), and other segments such as veterinary drugs (2.55%) and import/export trade (1.82%) [1].

Group 1 - The stock price of Harbin Sanlian Pharmaceutical Co., Ltd. (哈三联) increased by 2.00% on November 14, reaching 15.29 CNY per share, with a trading volume of 1.51 billion CNY and a turnover rate of 5.70%, resulting in a total market capitalization of 48.37 billion CNY [1] - Year-to-date, the stock price has risen by 58.45%, with a 10.00% increase over the last five trading days, a 16.63% increase over the last 20 days, and a 2.55% increase over the last 60 days [2] - The company has appeared on the "龙虎榜" (a stock market leaderboard) nine times this year, with the most recent appearance on June 3 [2] Group 2 - The company's main business revenue composition includes: large-volume infusion (32.00%), lyophilized powder injection (18.39%), solid preparations (17.39%), small-volume injections (14.34%), and others [2] - As of November 10, the number of shareholders is 39,600, a decrease of 2.98% from the previous period, while the average circulating shares per person increased by 3.07% to 4,419 shares [2] - For the period from January to September 2025, the company reported a revenue of 581 million CNY, a year-on-year decrease of 30.75%, and a net profit attributable to shareholders of -209 million CNY, a year-on-year decrease of 614.61% [2] Group 3 - Since its A-share listing, the company has distributed a total of 677 million CNY in dividends, with 158 million CNY distributed over the past three years [3]

Core Insights - The company, Ha Sanlian, reported that as of November 10, 2025, the number of shareholders is 39,589 [2] Company Information - Ha Sanlian has engaged with investors through an interactive platform to provide updates on shareholder numbers [2] - The specified date for the shareholder count is set for November 10, 2025, indicating a forward-looking perspective on shareholder engagement [2]

Core Points - The Shanghai Composite Index closed at 3993.35 points, remaining above the six-month moving average, with a slight decline of 0.24% [1] - The total trading volume of A-shares reached 1,270.245 billion yuan [1] - A total of 49 A-shares have surpassed the six-month moving average today, with notable stocks showing significant deviation rates [1] Summary by Category Stock Performance - Notable stocks with high deviation rates include: - Qudongli (驱动力) with a deviation rate of 5.91% and a daily increase of 7.05% [1] - Lubridge Information (路桥信息) with a deviation rate of 5.60% and a daily increase of 13.08% [1] - Beiyikang (倍益康) with a deviation rate of 4.75% and a daily increase of 7.60% [1] - Other stocks that just crossed the six-month moving average include: - Qianyuan Pharmaceutical (仟源医药) and *ST Jinke (*ST金科) with smaller deviation rates [1] Trading Activity - The trading turnover rate for Qudongli was 3.59%, while Lubridge Information had a turnover rate of 6.91% [1] - The stock with the highest turnover rate was Aipeng Medical (爱朋医疗) at 19.33% with a daily increase of 10.57% [1] Market Trends - The overall market shows a mix of stocks performing well above the six-month moving average, indicating potential bullish sentiment in certain sectors [1]

Group 1 - The company is developing a new product, Palivizumab injection, aimed at treating influenza A or B, specifically targeting the H3N2 subtype, which is a prevalent seasonal flu strain in humans [2] - The company confirmed that the Palivizumab injection is being researched as a next-generation product to address resistance to Oseltamivir and severe cases of influenza [2] - The company will continue to advance the progress of its research and development products [2]

Group 1 - The flu concept is experiencing renewed activity, leading to significant stock movements in related companies [1] - Te Yi Pharmaceutical has achieved two consecutive trading limits, indicating strong market interest [1] - Bo Hui Innovation has reached a 20% daily limit increase, reflecting positive investor sentiment [1] Group 2 - Panlong Pharmaceutical has also hit the daily limit, showcasing its strong performance in the market [1] - Other companies such as Zhongsheng Pharmaceutical, Ha Sanlian, and Jinhua Co. have seen their stocks rise in response to the flu concept's resurgence [1]

Core Points - The company, Ha Sanlian (002900), announced that it and its subsidiaries have no overdue guarantees, no litigation related to guarantees, and no losses incurred from being ruled against in guarantee-related lawsuits [1] Summary by Category Company Announcement - Ha Sanlian has confirmed that there are no overdue guarantees [1] - The company stated that it is not involved in any litigation concerning guarantees [1] - There are no losses that the company is required to bear due to adverse rulings in guarantee-related cases [1]

证券代码：002900 证券简称：哈三联 公告编号：2025-075 关于为全资子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 哈尔滨三联药业股份有限公司（以下简称"公司"或"哈三联"）于 2025 年 4 月 23 日召开的第四届董事会第二十一次会议及 2025 年 5 月 15 日召开的 2024 年年度股东大会审议通过了《关于 2025 年度向银行等金融机构申请综合授信额 度及为全资子公司提供担保的议案》，同意公司为 4 家全资子公司申请 2025 年度 综合授信额度提供总金额不超过 2 亿元的连带责任担保，被担保对象包括哈尔滨 裕阳进出口有限公司（以下简称"裕阳进出口"）、灵宝哈三联生物药业有限公司 （以下简称"灵宝哈三联"）、兰西哈三联制药有限公司（以下简称"兰西制药"）、 哈尔滨龙江动保生物科技有限公司（以下简称"龙江动保"）。 具体担保金额及保证期间按照合同约定执行。在上述额度范围内，股东大会 授权公司经营管理层办理和签署相关担保事宜及材料，有效期自公司 2024 年度 股东大会审议通过之日起至 202 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002900 证券简称：哈三联 公告编号：2025-071 哈尔滨三联药业股份有限公司 第四届董事会第二十七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、董事会会议召开情况 1、哈尔滨三联药业股份有限公司（以下或简称"公司"）第四届董事会第二十七次会议于2025年11月4日 以电子邮件、微信形式向全体董事发出通知。 2、本次会议于2025年11月6日以通讯表决的方式召开。 3、本次会议应出席董事9人，实际出席会议并表决的董事9人。 4、公司董事长秦剑飞先生主持本次会议，公司监事、总裁及董事会秘书列席会议。 表决情况如下： 1.01提名秦剑飞先生为第五届董事会非独立董事候选人； 表决情况：有效表决9票，同意9票，反对0票，弃权0票。 1.02 提名诸葛国民先生为第五届董事会非独立董事候选人； 表决情况：有效表决9票，同意9票，反对0票，弃权0票。 1.03 提名秦臻先生为第五届董事会非独立董事候选人； 5、本次会议的通知、召集和召开符合《中华人民共和国公司法》（以下简称"《公司法》 ...

Core Viewpoint - The company announced the convening of its 27th meeting of the fourth board of directors on November 6, 2025, to discuss the election of the fifth board of directors and the nomination of candidates for both non-independent and independent directors [1] Group 1 - The board of directors approved the proposal for the election of the fifth board of directors and the nomination of candidates for non-independent directors [1] - The company nominated Qin Jianfei, Zhuge Guomin, Qin Zhen, Liang Yanfei, and Qin Jiantao as candidates for non-independent directors [1] - The company nominated Liu Hongquan, Wang Dong, and Wei Jing as candidates for independent directors [1]